* participation in other clinical trials for the treatment or prevention of sars-cov-2 infection within 30 days before inclusion * hypersensitivity to any of the drugs or to any of its excipients. * ecg showing rhythm disturbances, qt interval\> 500 ms, conduction disturbances. * severe hepatic impairment. * concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin, lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron, quetiapine, ticagrelor, cisapride, astemizole, astemizol. * retinal pathology. * epilepsy. * myasthenia. * psoriasis. * methemoglobinemia. * porphyria. * pregnant or lactating women * contraindication to the study products

* participation in other clinical trials for the treatment or prevention of sars-cov-2 infection within 30 days before inclusion * hypersensitivity to any of the drugs or to any of its excipients. * ecg showing rhythm disturbances, qt interval\> 500 ms, conduction disturbances. * severe hepatic impairment. * concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin, lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron, quetiapine, ticagrelor, cisapride, astemizole, astemizol. * retinal pathology. * epilepsy. * myasthenia. * psoriasis. * methemoglobinemia. * porphyria. * pregnant or lactating women * contraindication to the study products

- participation in other clinical trials for the treatment or prevention of sars-cov-2 infection within 30 days before inclusion - hypersensitivity to any of the drugs or to any of its excipients. - ecg showing rhythm disturbances, qt interval> 500 ms, conduction disturbances. - severe hepatic impairment. - concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin, lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron, quetiapine, ticagrelor, cisapride, astemizole, astemizol. - retinal pathology. - epilepsy. - myasthenia. - psoriasis. - methemoglobinemia. - porphyria. - pregnant or lactating women - contraindication to the study products

- participation in other clinical trials for the treatment or prevention of sars-cov-2 infection within 30 days before inclusion - hypersensitivity to any of the drugs or to any of its excipients. - ecg showing rhythm disturbances, qt interval> 500 ms, conduction disturbances. - severe hepatic impairment. - concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin, lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron, quetiapine, ticagrelor, cisapride, astemizole, astemizol. - retinal pathology. - epilepsy. - myasthenia. - psoriasis. - methemoglobinemia. - porphyria. - pregnant or lactating women - contraindication to the study products